Improvement of the approach to definition of patient release criteria after radionuclide therapy
Current patient release criteria established in NRB-99/2009 relate to four radionuclides used in Russia that period of the document preparation. These criteria were calculated only considering the radionuclide decay. Thus, these criteria give conservative assessments which require the patient to sta...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Saint-Petersburg Research Institute of Radiation Hygiene after Professor P.V. Ramzaev
2023-06-01
|
| Series: | Радиационная гигиена |
| Subjects: | |
| Online Access: | https://www.radhyg.ru/jour/article/view/949 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849396909182025728 |
|---|---|
| author | L. A. Chipiga I. A. Zvonova A. V. Vodovatov A. V. Petryakova A. A. Stanzhevsky D. A. Vazhenina M. A. Smoliarchuk S. A. Ryzhov |
| author_facet | L. A. Chipiga I. A. Zvonova A. V. Vodovatov A. V. Petryakova A. A. Stanzhevsky D. A. Vazhenina M. A. Smoliarchuk S. A. Ryzhov |
| author_sort | L. A. Chipiga |
| collection | DOAJ |
| description | Current patient release criteria established in NRB-99/2009 relate to four radionuclides used in Russia that period of the document preparation. These criteria were calculated only considering the radionuclide decay. Thus, these criteria give conservative assessments which require the patient to stay in dedicated protected room (“hot” room) of the radiotherapy department for several days and do not allow to radionuclide therapy to be given in the outpatient hospital which certainly reduces the availability of this type of treatment. Consideration of the biological excretion of the radiopharmaceutical will be able to make the patient release criteria after radionuclide therapy significantly softer. Recently, new promising radionuclides and radiopharmaceuticals for therapy have appeared, the introduction of which into medical practice is obstructed by the lack of the patient release criteria. Current study is devoted to justification of improvement the approach to definition of patient release criteria after radionuclide therapy with promising and applied radiopharmaceuticals considering biological excretion of radiopharmaceutical. As examples, calculations of patient release criteria were performed for 177Lu-PSMA, 177Lu-DOTA-TATE, 131I-mIBG и Na131I. The dosimetric model used for calculation is based on the model which was used for definition of the current patient release criteria in NRB-99/2009. Additionally, the biological excretion of the radionuclide in radiopharmaceutical, which was assessed according to the published data, was considered. Two phases of biological excretion were evaluated for considered radiopharmaceuticals (fast and slow fractions). The main contribution of the radionuclide decrease in the patient’s body during the first hours after the injection is made by the fast-eliminated fraction. During 4-6 hours after the administration about 50% of these radiopharmaceuticals eliminated via urine. The calculation of patient release criteria were performed for slow-elimination fractions which characterize the decrease of radionuclide activity in the body after the patient release. The following effective half-lives were used: 177Lu-PSMA – 60 hours, 177Lu-DOTA-TATE – 100 hours, 131I-mIBG – 45 hours, Na131I – 7.5 days. The calculations demonstrate when planning a course of radionuclide therapy with four administrations of 177Lu-PSMA, the release of a patient is allowed at the dose rate of 20 μSv/h from the patient at the distance of 1 m; in case of radionuclide therapy with 177Lu-DOTA-TATE, release of a patient is allowed at the dose rate of 12 μSv/h. Considering the fast-eliminated fraction in the first hours after the administration, it can be assumed that more patients with normal renal function can undergo radionuclide therapy with 177Lu-PSMA in the outpatient hospital. Some patients after the 177Lu-PSMA administration and patients in the therapy with 177Lu-DOTA-TATE may be held in the department in the “hot” rooms for 1-2 days until the dose rate decrease to the acceptable levels. The consideration of biological excretion of radiopharmaceutical makes it possible to soften patient release criterion for 131I-mIBG by four times and for Na131I – by 10%. It will allow to release patients after radionuclide therapy earlier without reduce of radiation safety of people around the patient and will increase the capacity of radionuclide therapy department. |
| format | Article |
| id | doaj-art-25a5e523248f4e75bcfa76dc44326491 |
| institution | Kabale University |
| issn | 1998-426X |
| language | English |
| publishDate | 2023-06-01 |
| publisher | Saint-Petersburg Research Institute of Radiation Hygiene after Professor P.V. Ramzaev |
| record_format | Article |
| series | Радиационная гигиена |
| spelling | doaj-art-25a5e523248f4e75bcfa76dc443264912025-08-20T03:39:13ZengSaint-Petersburg Research Institute of Radiation Hygiene after Professor P.V. RamzaevРадиационная гигиена1998-426X2023-06-01162193110.21514/1998-426X-2023-16-2-19-31796Improvement of the approach to definition of patient release criteria after radionuclide therapyL. A. Chipiga0I. A. Zvonova1A. V. Vodovatov2A. V. Petryakova3A. A. Stanzhevsky4D. A. Vazhenina5M. A. Smoliarchuk6S. A. Ryzhov7Saint-Petersburg Research Institute of Radiation Hygiene after Professor P.V. Ramzaev, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing; A. Granov Russian Scientific Center of Radiology and Surgical Technologies of the Ministry of Health of the Russian Federation; Almazov National Medical Research Centre of the Ministry of Health of the Russian FederationSaint-Petersburg Research Institute of Radiation Hygiene after Professor P.V. Ramzaev, Federal Service for Surveillance on Consumer Rights Protection and Human WellbeingSaint-Petersburg Research Institute of Radiation Hygiene after Professor P.V. Ramzaev, Federal Service for Surveillance on Consumer Rights Protection and Human WellbeingSaint-Petersburg Research Institute of Radiation Hygiene after Professor P.V. Ramzaev, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing; The City Hospital No 40 of the Kurortny DistrictA. Granov Russian Scientific Center of Radiology and Surgical Technologies of the Ministry of Health of the Russian FederationA. Granov Russian Scientific Center of Radiology and Surgical Technologies of the Ministry of Health of the Russian Federation“Medicine and Nuclear Technologies” LLC; Association of Nuclear MedicineAssociation of Medical Physicists of Russia; Research and Practical Clinical Centre of Diagnostics and Telemedicine Technologies of Moscow Healthcare Department; Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of the Ministry of Health of the Russian FederationCurrent patient release criteria established in NRB-99/2009 relate to four radionuclides used in Russia that period of the document preparation. These criteria were calculated only considering the radionuclide decay. Thus, these criteria give conservative assessments which require the patient to stay in dedicated protected room (“hot” room) of the radiotherapy department for several days and do not allow to radionuclide therapy to be given in the outpatient hospital which certainly reduces the availability of this type of treatment. Consideration of the biological excretion of the radiopharmaceutical will be able to make the patient release criteria after radionuclide therapy significantly softer. Recently, new promising radionuclides and radiopharmaceuticals for therapy have appeared, the introduction of which into medical practice is obstructed by the lack of the patient release criteria. Current study is devoted to justification of improvement the approach to definition of patient release criteria after radionuclide therapy with promising and applied radiopharmaceuticals considering biological excretion of radiopharmaceutical. As examples, calculations of patient release criteria were performed for 177Lu-PSMA, 177Lu-DOTA-TATE, 131I-mIBG и Na131I. The dosimetric model used for calculation is based on the model which was used for definition of the current patient release criteria in NRB-99/2009. Additionally, the biological excretion of the radionuclide in radiopharmaceutical, which was assessed according to the published data, was considered. Two phases of biological excretion were evaluated for considered radiopharmaceuticals (fast and slow fractions). The main contribution of the radionuclide decrease in the patient’s body during the first hours after the injection is made by the fast-eliminated fraction. During 4-6 hours after the administration about 50% of these radiopharmaceuticals eliminated via urine. The calculation of patient release criteria were performed for slow-elimination fractions which characterize the decrease of radionuclide activity in the body after the patient release. The following effective half-lives were used: 177Lu-PSMA – 60 hours, 177Lu-DOTA-TATE – 100 hours, 131I-mIBG – 45 hours, Na131I – 7.5 days. The calculations demonstrate when planning a course of radionuclide therapy with four administrations of 177Lu-PSMA, the release of a patient is allowed at the dose rate of 20 μSv/h from the patient at the distance of 1 m; in case of radionuclide therapy with 177Lu-DOTA-TATE, release of a patient is allowed at the dose rate of 12 μSv/h. Considering the fast-eliminated fraction in the first hours after the administration, it can be assumed that more patients with normal renal function can undergo radionuclide therapy with 177Lu-PSMA in the outpatient hospital. Some patients after the 177Lu-PSMA administration and patients in the therapy with 177Lu-DOTA-TATE may be held in the department in the “hot” rooms for 1-2 days until the dose rate decrease to the acceptable levels. The consideration of biological excretion of radiopharmaceutical makes it possible to soften patient release criterion for 131I-mIBG by four times and for Na131I – by 10%. It will allow to release patients after radionuclide therapy earlier without reduce of radiation safety of people around the patient and will increase the capacity of radionuclide therapy department.https://www.radhyg.ru/jour/article/view/949nuclear medicineradionuclide therapyradiopharmaceuticalpatient release criteriaradiation safetyeffective half-life |
| spellingShingle | L. A. Chipiga I. A. Zvonova A. V. Vodovatov A. V. Petryakova A. A. Stanzhevsky D. A. Vazhenina M. A. Smoliarchuk S. A. Ryzhov Improvement of the approach to definition of patient release criteria after radionuclide therapy Радиационная гигиена nuclear medicine radionuclide therapy radiopharmaceutical patient release criteria radiation safety effective half-life |
| title | Improvement of the approach to definition of patient release criteria after radionuclide therapy |
| title_full | Improvement of the approach to definition of patient release criteria after radionuclide therapy |
| title_fullStr | Improvement of the approach to definition of patient release criteria after radionuclide therapy |
| title_full_unstemmed | Improvement of the approach to definition of patient release criteria after radionuclide therapy |
| title_short | Improvement of the approach to definition of patient release criteria after radionuclide therapy |
| title_sort | improvement of the approach to definition of patient release criteria after radionuclide therapy |
| topic | nuclear medicine radionuclide therapy radiopharmaceutical patient release criteria radiation safety effective half-life |
| url | https://www.radhyg.ru/jour/article/view/949 |
| work_keys_str_mv | AT lachipiga improvementoftheapproachtodefinitionofpatientreleasecriteriaafterradionuclidetherapy AT iazvonova improvementoftheapproachtodefinitionofpatientreleasecriteriaafterradionuclidetherapy AT avvodovatov improvementoftheapproachtodefinitionofpatientreleasecriteriaafterradionuclidetherapy AT avpetryakova improvementoftheapproachtodefinitionofpatientreleasecriteriaafterradionuclidetherapy AT aastanzhevsky improvementoftheapproachtodefinitionofpatientreleasecriteriaafterradionuclidetherapy AT davazhenina improvementoftheapproachtodefinitionofpatientreleasecriteriaafterradionuclidetherapy AT masmoliarchuk improvementoftheapproachtodefinitionofpatientreleasecriteriaafterradionuclidetherapy AT saryzhov improvementoftheapproachtodefinitionofpatientreleasecriteriaafterradionuclidetherapy |